M&A

News

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

News

Jasper and Kira merge to build immune-focused biotech

Faced with the prospect of running out of cash, Jasper Therapeutics has merged with Kira Pharma, fortified by $132m in new private funding.

News

Samsung Biologics agrees $1.81bn takeover of PolyPeptide

Samsung Biologics has agreed to buy PolyPeptide, a Swiss CDMO, in what is thought to be South Korea's largest biopharma acquisition to date.

News

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

Sales & Marketing

pharmaphorum podcast Episode 268 - Andrea Carta Mantiglia, BonelliErede

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, discusses M&A in Europe.

M&A

Editor's Picks